CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 8 enrolled
Drug / intervention
perflutren lipid microspheresdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00584402
NCT00584402N/ACompleted
CompareCT.gov

Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation

University of California, Davis·interventional·Posted Jan 2, 2008·Updated Jul 11, 2017

In Brief

A clinical study evaluating perflutren lipid microspheres for Liver Neoplasms. Completed, enrolled 8 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the efficacy of the Definity (perflutren lipid microsphere Injectable Suspension) ultrasound contrast agent in identifying small tumors (hepatomas \& metastases) within the liver. Primary objective: To estimate the increase in conspicuity of small intrahepatic tumors with contrast-enhanced sonography Secondary Objectives: To estimate the effect of tumor type, size, location and depth on the conspicuity of small tumors on contrast-enhanced sonography

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Neoplasms
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2, 2008
Enrollment StartApr 1, 2007
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.5 years ago

Interventions

perflutren lipid microspheresdrug

perflutren lipid microspheres IV in 0.1 cc doses, as needed, to enhance lesion conspicuity